R

Rhone Ma Holdings Bhd
KLSE:RHONEMA

Watchlist Manager
Rhone Ma Holdings Bhd
KLSE:RHONEMA
Watchlist
Price: 0.695 MYR -1.42%
Market Cap: 153.8m MYR
Have any thoughts about
Rhone Ma Holdings Bhd?
Write Note

Relative Value

The Relative Value of one RHONEMA stock under the Base Case scenario is 0.987 MYR. Compared to the current market price of 0.695 MYR, Rhone Ma Holdings Bhd is Undervalued by 30%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RHONEMA Relative Value
Base Case
0.987 MYR
Undervaluation 30%
Relative Value
Price
R
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
98
vs Industry
77
Median 3Y
0.8
Median 5Y
0.8
Industry
2.6
Forward
0.7
vs History
96
vs Industry
34
Median 3Y
12.4
Median 5Y
12.7
Industry
23
Forward
11.1
vs History
74
vs Industry
45
Median 3Y
5.7
Median 5Y
9
Industry
17.8
vs History
31
vs Industry
33
Median 3Y
-16
Median 5Y
-10.9
Industry
25.4
vs History
98
vs Industry
65
Median 3Y
1
Median 5Y
1
Industry
2.2
vs History
98
vs Industry
80
Median 3Y
0.8
Median 5Y
0.9
Industry
2.8
Forward
0.7
vs History
98
vs Industry
66
Median 3Y
2.9
Median 5Y
3
Industry
5.4
vs History
98
vs Industry
44
Median 3Y
6.4
Median 5Y
7
Industry
13.7
Forward
5.9
vs History
98
vs Industry
42
Median 3Y
7.6
Median 5Y
8.3
Industry
17.2
Forward
7
vs History
71
vs Industry
46
Median 3Y
5.3
Median 5Y
9.4
Industry
16.5
vs History
47
vs Industry
34
Median 3Y
5.5
Median 5Y
5.5
Industry
19.3
vs History
98
vs Industry
65
Median 3Y
0.9
Median 5Y
0.9
Industry
2

Multiples Across Competitors

RHONEMA Competitors Multiples
Rhone Ma Holdings Bhd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
MY
Rhone Ma Holdings Bhd
KLSE:RHONEMA
154.9m MYR 0.7 12.5 5.5 6.4
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
746.8B USD 18.3 89.2 48 53.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.4 27.8
US
Johnson & Johnson
NYSE:JNJ
365.6B USD 4.2 24.9 12 15.7
US
Merck & Co Inc
NYSE:MRK
249.1B USD 3.9 20.5 10.4 12.4
CH
Roche Holding AG
SIX:ROG
208.6B CHF 3.6 18.1 10.2 12.1
CH
Novartis AG
SIX:NOVN
181.4B CHF 4.2 12.6 10 14.8
UK
AstraZeneca PLC
LSE:AZN
159.6B GBP 4.1 31.4 169.3 253.8
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
MY
R
Rhone Ma Holdings Bhd
KLSE:RHONEMA
Average P/E: 30.5
12.5
23%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
89.2
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
24.9
-22%
US
Merck & Co Inc
NYSE:MRK
20.5
7 336%
CH
Roche Holding AG
SIX:ROG
18.1
32%
CH
Novartis AG
SIX:NOVN
12.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.4
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Discover More
Back to Top